Form 4: Axsome CFO Sells Shares After Option Exercise

Axsome Therapeutics' Chief Financial Officer, Nick Pizzie, exercised stock options and subsequently sold 12,000 shares of common stock under a pre-approved 10b5-1 plan.

Summary

• Nick Pizzie, Chief Financial Officer of Axsome Therapeutics, Inc. (AXSM), reported transactions on January 22, 2026.
• Exercised 12,000 stock options at an exercise price of $3.5 per share, which were held for 8 years prior to the 10-year expiration date.
• Subsequently sold 12,000 shares of common stock at a weighted average price of $187.92 per share.
• The sale price for the common stock ranged between $185.09 and $191.12.
• All transactions were conducted pursuant to a pre-approved 10b5-1 plan.
• Following these transactions, Pizzie directly beneficially owns 42,588 shares of common stock and indirectly owns 488 shares through UTMA accounts.
• Pizzie also holds 105,000 stock options with an exercise price of $3.5, exercisable from May 16, 2019, and expiring on May 16, 2028.

Sentiment

Score: 5

Explanation: Neutral. The filing reports a routine insider transaction (exercise and sell) executed under a 10b5-1 plan, which is a common practice for executives to manage their equity holdings. It doesn't inherently signal positive or negative company performance.

Positives

• The transaction was executed under a pre-approved 10b5-1 plan, indicating a planned sale rather than an immediate reaction to new information.
• The sale occurred at a high price point ($187.92 weighted average) relative to the exercise price ($3.5), indicating significant personal gain for the insider.

Negatives

• An insider sale, even if planned, can sometimes be perceived negatively by the market, as it reduces the insider's direct equity stake.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May observe a slight reduction in direct insider ownership, but the 10b5-1 plan mitigates concerns about opportunistic selling.

Key Dates

Recommendation

This Form 4 filing details a pre-planned insider transaction by the CFO, involving the exercise of stock options and the subsequent sale of shares. Such transactions, especially when executed under a 10b5-1 plan, are generally considered routine for executive compensation and personal financial planning. They do not typically indicate a change in the company's fundamental outlook or performance. Therefore, the filing itself does not provide a basis for a 'buy' or 'sell' recommendation, suggesting a 'hold' position based solely on this specific disclosure.

Keywords

Axsome Therapeutics, AXSM, Nick Pizzie, CFO, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Beneficial Ownership